This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| chlorpromazine | |
|---|---|
| Name | chlorpromazine |
| Routes of administration | oral, intramuscular, intravenous |
| Class | typical antipsychotic, phenothiazine |
| Metabolism | hepatic (CYP) |
| Excretion | renal |
chlorpromazine
Chlorpromazine is a first-generation antipsychotic of the phenothiazine class developed in the early 20th century and widely influential in psychiatry, neurology, and emergency medicine. It marked a paradigm shift in treatment of psychosis and acute agitation and has been used in a range of indications including schizophrenia, bipolar disorder, and severe nausea. The drug’s discovery and adoption intersected with major figures and institutions in mid-20th century medicine and public health, affecting practices in hospitals, asylums, and pharmacology research centers.
Chlorpromazine emerged from research programs associated with Rhône-Poulenc and was first synthesized during collaborations linked to French chemical industry laboratories. Early clinical application was advanced through work at institutions such as the Hôpital Sainte-Anne and the influence of psychiatrists connected to Pierre Deniker and contemporaries in post‑World War II European psychiatry. Its introduction into clinical practice overlapped with major postwar developments involving World Health Organization, National Institute of Mental Health, and national formularies, catalyzing deinstitutionalization movements associated with policymakers in the United Kingdom, United States, and France. Adoption of chlorpromazine changed hospital practices at facilities like Bellevue Hospital and prompted regulatory review by entities including the Food and Drug Administration and similar agencies in Canada and Australia.
Clinically, chlorpromazine has been indicated for acute and chronic psychotic disorders and behavioral disturbances managed in settings such as Johns Hopkins Hospital, Massachusetts General Hospital, and psychiatric departments at universities like Harvard Medical School, University of Oxford, and University of Melbourne. It has been used for schizophrenia, schizoaffective disorder, severe mania in bipolar disorder, and as an adjunct in refractory depression assessed in trials funded by institutions such as the National Institutes of Health. Additional uses include antiemetic applications in oncology protocols at centers like MD Anderson Cancer Center and antipruritic or sedation interventions in emergency departments at hospitals affiliated with Imperial College London and University College London. Off‑label and niche uses were documented in case series from clinics linked to Karolinska Institutet and the Mayo Clinic.
Chlorpromazine’s pharmacodynamic profile includes antagonism at dopaminergic receptors first characterized in laboratories associated with Max Planck Society and pharmacology groups at University of Cambridge. It blocks D2 receptors and interacts with adrenergic, histaminergic H1, and muscarinic acetylcholine receptors; these receptor interactions were elucidated in biochemical studies at institutions such as Salk Institute and University of California, San Francisco. Hepatic metabolism involves cytochrome P450 isoenzymes studied in departments at University of Toronto and UCL Queen Square Institute of Neurology. Pharmacokinetic parameters were described in pharmacology departments at Karolinska Institutet and clinical pharmacology units at King's College London. The drug’s sedative and antiemetic properties are attributed to H1 and dopamine receptor blockade examined in research collaborations with the Royal College of Physicians and oncology centers like Memorial Sloan Kettering Cancer Center.
Adverse effect profiles were documented in surveillance programs run by regulatory bodies such as the European Medicines Agency and national health services like the NHS. Common effects include extrapyramidal symptoms and tardive dyskinesia characterized in movement disorder clinics at National Hospital for Neurology and Neurosurgery and University College Hospital. Anticholinergic effects, hypotension due to alpha-adrenergic blockade, and sedation were reported in clinical reviews from Cleveland Clinic and academic centers at Yale School of Medicine. Serious complications, including neuroleptic malignant syndrome and QT prolongation relevant to cardiology services at St Bartholomew's Hospital and Royal Brompton Hospital, were subject of case reports and guideline updates from professional societies like the American Psychiatric Association and European Society of Cardiology.
Clinically significant interactions involve agents modulating cytochrome P450 enzymes documented by drug safety units at Medicines and Healthcare products Regulatory Agency and pharmacovigilance divisions at FDA. Co-administration with other dopamine antagonists and centrally acting sedatives used in hospital formularies at Guy's and St Thomas' NHS Foundation Trust or oncologic regimens at Royal Marsden Hospital increases extrapyramidal risk. Additive QT‑prolonging effects were highlighted in cardiology consortia including European Heart Rhythm Association and oncology collaborations at Johns Hopkins Kimmel Cancer Center when combined with agents like certain macrolide antibiotics referenced in guidance from Centers for Disease Control and Prevention.
Dosage regimens were standardized in formularies from institutions such as British National Formulary committees and clinical guidelines issued by the World Federation of Societies of Biological Psychiatry. Typical oral and parenteral dosing strategies used in inpatient psychiatry wards at Bellevue Hospital and emergency protocols at Royal London Hospital emphasize titration based on clinical response and tolerability, with monitoring practices aligned to recommendations from American College of Cardiology for ECG surveillance and from Royal College of Psychiatrists for movement disorder screening.
Chlorpromazine’s introduction had broad social and cultural impact analyzed by historians at universities including University of Chicago and Columbia University. It influenced film and literature portrayals of psychiatry in works associated with BBC and The New York Times coverage, and affected policy debates involving advocacy groups such as Mental Health America and Mind (charity). The drug’s role in deinstitutionalization intersected with legal and social frameworks involving courts like United States Supreme Court decisions on civil commitment and public health initiatives coordinated by World Health Organization programs. Ongoing discussions about access and generic formulations reflect pharmaceutical industry dynamics involving companies like Novartis and generics producers governed by trade frameworks referenced by World Trade Organization.
Category:Antipsychotics